Search This Blog

Monday, May 2, 2022

Acadia: FDA to re-review Nuplazid for Alzheimer's symptoms

 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a virtual meeting of the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee to review the resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) has been scheduled for June 17, 2022. The target action date for the application is August 4, 2022.

https://finance.yahoo.com/news/acadia-pharmaceuticals-announces-fda-advisory-200500805.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.